Burton G. Malkiel - May 2, 2023 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
Director
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Stock symbol
TBPH
Transactions as of
May 2, 2023
Transactions value $
$0
Form type
4
Date filed
5/4/2023, 06:41 PM
Previous filing
Apr 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $0 +9.13K +9.99% $0.00 101K May 2, 2023 Direct
holding TBPH Ordinary Shares 15K May 2, 2023 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBPH Share Option (Right to Buy) Award $0 +22K $0.00 22K May 2, 2023 Ordinary Shares 22K $10.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.